Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03394053 · ClinicalTrials.gov registry record
The Mechanistic Biology of Primary Immunodeficiency Disorders
A clinical trial of Primary Immunodeficiency Disorders, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- 2,500
- Enrollment target
- 2
- Study locations
NCT03394053 is a study of Primary Immunodeficiency Disorders that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2,500 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT03394053, a study of Primary Immunodeficiency Disorders, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- 2,500 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: Primary immunodeficiency disorders, or PIDs, are diseases that weaken the immune system. This makes it easier for a person to get sick. Some PIDs are mild and may not be diagnosed until later in life. Other kinds are severe and can be identified shortly after birth. Researchers want to learn more about PIDs by comparing data from relatives and healthy volunteers to people with a PID. Objective: To learn more about PIDs, including their genetic causes. Eligibility: People ages 0-90 with a PID or their healthy biological relatives the same ages Healthy volunteers ages 18-75 Design: Participants will be screened with a medical history, physical exam, and HIV blood test. They may have a pregnancy test. Participants may repeat the screening tests. Blood taken at screening will be used for genetic tests and research tests. Participants will be told test results that affect their health. Some blood will be stored for future research. Adult participants with a PID may have a small piece of skin removed. The area will be numbed. A small tool will take a piece of skin about the size of a pencil eraser. Researchers may collect fluid or tissue samples from PID participants regular medical care. They will use them for research tests. Participants with a PID will have 3 follow-up visits over 10 years (for infants, 2 years). Visits will include a physical exam, medical history, and blood draw. Participants with a PID and their relatives will be called once a year for 10 years. They will talk about how they are feeling and if they have developed any new symptoms or illnesses. ...
Conditions Studied
Study Locations (2)
District of Columbia
- Children's National Health System (CNHS) - Washington D.C.
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2018-05-30 |
| Est. Completion | 2040-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03394053
The ClinicalTrials.gov registry entry for NCT03394053 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Immunodeficiency Disorders appearing as the primary indexed condition, and to 0 interventions.
NCT03394053 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT03394053 about?
NCT03394053 is a clinical study titled "The Mechanistic Biology of Primary Immunodeficiency Disorders". Background: Primary immunodeficiency disorders, or PIDs, are diseases that weaken the immune system. This makes it easier for a person to get sick. Some PIDs are mild and may not be diagnosed until later in life. Other kinds are severe and can be identified shortly after birth. Researchers want to ...
What is the current status of trial NCT03394053?
This trial is currently recruiting. The enrollment target is 2,500 participants. The study started on 2018-05-30. Estimated completion is 2040-12-31.
What conditions does trial NCT03394053 study?
This clinical trial studies the following conditions: Primary Immunodeficiency Disorders.
Who is sponsoring clinical trial NCT03394053?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03394053 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.